Life MD Financial Results
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(in whole numbers, unaudited)
Fourth Quarter Ended December 31,
2023
2022
Year Ended December 31,
2023
2022
Net loss attributable to common shareholders
Interest expense (excluding amortization of debt discount)
Depreciation, amortization and accretion expense
Amortization of debt discount
Loss (gain) on debt extinguishment
Financing transactions expense
Litigation costs
Inventory and reserve adjustments
Deferred revenue adjustment
Severance costs
Acquisitions expenses
Change in fair value of contingent consideration
$
(4,508,664)
$
(12,711,912)
(23,702,242)
$
522,241
1,959,468
728,856
1,340,626
1,755,656
6,767,447
(48,641,909)
820,946
4,044,056
100,444
333,939
325,198
(63,400)
38,431
98,333
773,932
250,348
168,600
168,162
1,594,930
1,685,521
404,694
699,057
637,324
929,718
2,918,942
2,918,942
17,400
30,909
181,824
25,092
360,914
127,539
158,047
(2,614,000)
Goodwill and intangible asset impairment charges
6,127,596
392,692
(5,101,000)
8,862,596
Insurance acceptance readiness
252,250
318,884
Sarbanes Oxley readiness
151,248
199,824
Accrued interest on Series B Convertible Preferred Stock
114,685
506,991
Foreign exchange (gain) loss
368,793
393,147
1,165,412
455,000
1,078,389
Taxes
428,000
360,700
Dividends
1,399,560
812,562
Stock-based compensation expense
3,645,607
1,884,614
Net income attributable to noncontrolling interests
Adjusted EBITDA
509,880
360,168
498,378
5,371,450
12,489,343
2,756,935
360,700
3,250,250
13,734,614
514,632
$
5,488,861
990,899
$
11,976,540
(14,146,991)View entire presentation